Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
News Briefing channel feed
Palvella’s reverse merger with Pieris; AbbVie’s VC arm invests in anti-aging startup
11 months ago
Telix's $397M convertible bond offering; Scynexis records a $10M milestone
11 months ago
Grünenthal inks a deal with Valinor; Valneva gets $41M from CEPI
11 months ago
Rona Therapeutics raises $35M; Actuate now plans for $22M IPO
11 months ago
Boehringer plans to again increase R&D spending; Valneva, Pfizer to advance Lyme vaccine candidate
11 months ago
SK to pay up to $571M in new radiopharma deal; Aslan lets go of all employees
11 months ago
SOTIO, Biocytogen to jointly develop antibodies; Pliant's mid-stage liver disease data
11 months ago
Evofem inks women’s health deal; AusperBio brings in $37M
12 months ago
Ideaya raises $302M; AbbVie to seek approval in giant cell arteritis
12 months ago
Faron details clinical plans for MDS drug; Cara to seek 'strategic' options
12 months ago
Ideaya aims to raise $263M; Immuneel extends Series A with $12M
Last year
Kymera's stock rises after derma investigation expands; Ligand buys Apeiron
Last year
Vanqua raises $45M; Aerovate to look for strategic alternatives
Last year
Innovent reworks deal with IASO; Granza raises $7M
Last year
Yuhan, Ubix ink licensing deal; Xenpozyme's royalty deal
Last year
Tracon to seek ‘strategic’ options; Ovid to lay off 17 workers
Last year
Savara’s $100M offering; New biotech to test Eisai drug in Ph2
Last year
Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience
Last year
Taysha’s $75M offering; Augustine raises €17M
Last year
Zealand Pharma aims to raise $900M; Boehringer discontinues three Phase 2 trials
Last year
Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down
Last year
Layoffs at Ginkgo and Xellia; Melodia and Alivexis ink $275M partnership
Last year
Forbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure
Last year
A new obesity biotech; UroGen aims to raise $107M
Last year
First page
Previous page
7
8
9
10
11
12
13
Next page
Last page